The place for the tricyclic antidepressants in the treatment of depression

Australian and New Zealand Journal of Psychiatry

Volumn 33, Issue 3, 1999, Pages 323-327

  Boyce, Philip ^a   Judd, Fiona ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Depression; Melancholia; Side effect; Suicide; Tolerability; Tricyclic antidepressant

Indexed keywords

SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; CONSTIPATION; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; NAUSEA; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SOMNOLENCE; TREATMENT INDICATION; VERTIGO; VISUAL DISORDER;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSION; HUMANS; PSYCHIATRY; SEROTONIN UPTAKE INHIBITORS; SUICIDE; TREATMENT OUTCOME;

EID: 0032994765     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1614.1999.00580.x     Document Type: Article

References (39)

1. Burrows GD, Norman TR. Depression. Principles of contemporary management. Current Therapeutics 1997; 38:19-27.
2. Harrison G. New or old antidepressants? New is better. British Medical Journal 1994; 309:1280-1282.
3. Beerworth EE, Tiller JWG. Liability in prescribing choice: the example of the antidepressants. Australian and New Zealand Journal of Psychiatry 1998; 32:560-566.
4. Parker G, Hadzi-Pavlovic D, Boyce P. Endogenous depression as a construct: a quantitative analysis of the literature and a study of clinician judgements. Australian and New Zealand Journal of Psychiatry 1989; 23:357-368.
5. Quality Assurance Project. A treatment outline for depressive disorder. Australian and New Zealand Journal of Psychiatry 1983; 17:129-146.
6. Elkin I, Shea MT, Watkins JT et al. National Institute of Mental Health treatment of depression collaborative research program: general effectiveness of treatments. Archives of General Psychiatry 1989; 46:971-982.
7. Persons JB, Thase ME, Crits-christoph P. The role of psychotherapy in the treatment of depression. Archives of General Psychiatry 1996; 53:283-290.
8. Mynors-Wallis LM, Gath DH, Lloyd-Thomas AR, Tomlinson D. Randomised controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care. British Medical Journal 1995; 310:441-445.
9. Gloaguen V, Cottraux J, Cucherat M, Blackburn I-M. A meta-analysis of the effects of cognitive therapy in depressed patients. Journal of Affective Disorders 1998; 49:59-72.
10. American Psychiatric Association. Practice guideline for major depressive disorder in adults. American Journal of Psychiatry 1993: 150(Suppl. 4): 1-26.
11. Peselow E, Sanfilipo M, DiFiglia C, Fieve R. Melancholic/endogenous depression and response to somatic treatment and placebo. American Journal of Psychiatry 1992; 149:1324-1334.
12. Song F, Freemantle N, Sheldon T, House A, Watson P, Long A, Mason J. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. British Medical Journal 1993; 306:683-687.
13. Montgomery SA, Kasper S. Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. International Clinical Psychopharmacology 1995; 9(Suppl. 4): 33-40.
14. Lima MS, Moncrieff J. 2. A comparison of drugs versus placebo for the treatment of dysthymia: a systematic review. Cochrane Database of Systematic Reviews. Issue 4. Oxford, 1998.
15. Anderson IM, Tomenson BM. The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. Journal of Psychopharmacology 1994: 8:238-249.
16. Hotopf M, Hardy R, Lewis G. Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. British Journal of Psychiatry 1997; 170:120-127.
17. Joffe R, Sokolov S. Streiner D. Antidepressant treatment of depression: a metanalysis. Canadian Journal of Psychiatry 1998; 41:613-616.
18. Garattini S, Barbui C. Saraceno B. Antidepressant agents: from tricyclics to serotonin uptake inhibitors. Psychological Medicine 1998; 28:1169-1178.
19. Kasper S. Efficacy of antidepressants in the treatment of severe depression: the place of mirtazapine. Journal of Clinical Psychopharmacology 1997; 17(Suppl. 2):19S-28S.
20. Roose SP, Classman AH, Attia E, Woodring S. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. American Journal of Psychiatry 1994; 151:1735-1739.
21. Vestergaard P, Gram LF, Kragh-Sorensen P, Bech P, Reisby N, Bolwig TG. Therapeutic potentials of recently introduced antidepressants. Danish University Antidepressant Group. Psychopharmacological Services 1993; 10:190-198.
22. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Journal of Affective Disorders 1990; 18:289-299.
23. Danish University Antidepressant Group. Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. Journal of Affective Disorders 1993; 28:105-116.
24. Perry PJ. Pharmacotherapy for major depression with melancholic features: relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. Journal of Affective Disorder 1996; 39:1-6.
25. Tignol J, Stoker MJ, Dunbar GC. Paroxetine in the treatment of melancholia and severe depression. International Clinical Psychopharmacology 1992; 7:91-94.
26. Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. British Medical Journal 1995; 310:1433-1438.
27. Martin RM, Hilton SR, Kerry SM, Richards NM. General practitioners' perceptions of the tolerability of antidepressant drugs: a comparison of selective serotonin reuptake inhibitors and tricyclic antidepressants. British Medical Journal 1997; 314:646-651.
28. Trindale E, Menon D. Selective serotonin reuptake inhibitors (SSRIs) for major depression. Part 1. Evaluation of the clinical literature. Report 3E. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 1997.
29. Mitchell PB. The new antidepressants: a guide for GPs. Modern Medicine 1994; 37:16-20.
30. Zajecka J, Mitchell S, Fawcett J. Treatment-emergent changes in sexual function with selective serotonin reuptake inhibitors as measured with the Rush Sexual Inventory. Psychopharmacology Bulletin 1997; 33:755-760.
31. Martin TG. Serotonin syndrome. Annals of Emergency Medicine 1996; 28:520-526.
32. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. American Journal of Psychiatry 1996; 153:311-320.
33. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. Journal of Clinical Psychopharmacology 1996; 16:356-362.
34. Henry JA, Alexander CA, Sener EK. Relative mortality from overdose of antidepressants. British Medical Journal 1995; 310:221-224.
35. Inskip HM, Harris EC, Barraclough B. Lifetime risk of suicide for affective disorder, alcoholism and schizophrenia. British Journal of Psychiatry 1998; 172:35-37.
36. Isacsson G, Holmgren P, Wasserman D, Bergman U. Authors' reply. British Medical Journal 1994; 308:916.
37. Edwards JG. Suicide and antidepressants. British Medical Journal 1995; 310:205-206.
38. Dudley MJ, Kelk NJ, Florio TM. Howard JP, Waters BGH. Suicide among young Australians, 1964-1993: an interstate comparison of metropolitan and rural trends. Medical Journal of Australia 1998; 169:77-80.
39. Buckley NA, Whyte IM, Dawson AH, McManus PR, Ferguson NW. Correlations between prescriptions and drugs taken in self-poisoning. Medical Journal of Australia 1995: 162:194-197.